Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma

Authors

Institutions

Publication Details

Journal
Clinical Lymphoma Myeloma & Leukemia
Published
2025-05-03
DOI
https://doi.org/10.1016/j.clml.2025.04.020
Citations
6
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
8.83

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma

Brenda Cooper, Junyu Ding, Stéphane Doucet, Amitkumar Mehta et al.
6 citations
Clinical Lymphoma Myeloma & Leukemia
Lymphoma Diagnosis and Treatment
8.83
article

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma

Brenda Cooper, Junyu Ding, Stéphane Doucet, Amitkumar Mehta, Walter Hanel, Lapo Alinari, Dina Stroopinsky, Alexey Valeryevich Danilov, Patrick B. Johnston, Tao Long, Aleksander Chudnovsky, Sarit Assouline, Deborah Berg
article en
6 citations

Abstract

No abstract available for this paper.
Clinical Lymphoma Myeloma & LeukemiaVol. 25(11)
University Hospitals of Cleveland (US), Jewish General Hospital (CA), University of Alabama at Birmingham (US), City of Hope (US), Mayo Clinic in Arizona (US), Takeda (United States) (US), Centre Hospitalier de l’Université de Montréal (CA), The Ohio State University (US)
Takeda Pharmaceuticals U.S.A.
Zero hunger
Openalex Percentile: Top 2%
Lymphoma Diagnosis and Treatment
8.83
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma — Brenda Cooper, Junyu Ding, et al. · Clinical Lymphoma Myeloma & Leukemia (2025) | TGRS Research Map | TGRS